NRAS and melanoma: We found that both the BRAF-mutated 1205Lu and NRAS-mutated WM1366 melanoma cell lines retain their sensitivity to dinaciclib when grown as 3D collagen-implanted spheroids, suggesting that modulating the tumor microenvironmental conditions does not increase resistance to this compound.